1279P - Factors Predicting Worse Outcomes in Patients with N0 Lung Adenocarcinoma of 3cm or Smaller

Date 09 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancer in Adolescents
Non-Small-Cell Lung Cancer, Early Stage
Lung and other Thoracic Tumours
Presenter Jung-Jyh Hung
Citation Annals of Oncology (2017) 28 (suppl_5): v453-v456. 10.1093/annonc/mdx381
Authors J. Hung, W. Hsu
  • Department Of Surgery, Taipei Veterans General Hospital, 11217 - Taipei/TW

Abstract

Background

The role of adjuvant chemotherapy for patients with stage I non-small cell lung cancer remains unknown. The prognostic value of histological subtypes in resected node-negative small-sized lung adenocarcinoma has not been widely investigated. This study investigated the prognostic factors in patients with node-negative lung adenocarcinoma of 3cm or smaller to find potential candidates for adjuvant chemotherapy.

Methods

A total of 746 patients with completely resected node-negative lung adenocarcinoma of 3cm or smaller were included in the study. Prognostic factors for overall survival or probability of freedom from recurrence (FFR) were investigated.

Results

The 5-year overall survival and recurrence-free rates were 86.8% and 84.8%, respectively. During follow-up, 59 (7.9%) patients developed recurrence. Univariate analysis showed that micropapillary/solid predominant group had significantly lower probability of FFR (P = 0.001) in node-negative lung adenocarcinoma of 3cm or smaller. Older age (P = 0.007), greater tumor size (P = 0.006), and micropapillary/solid predominant group (P = 0.031) had significantly lower probability of FFR in multivariate analysis.

Conclusions

The new adenocarcinoma classification has significant impact on recurrence in node-negative lung adenocarcinoma of 3cm or smaller. Patients with micropapillary/solid predominant pattern have significant higher risk for recurrence.

Clinical trial identification

N/A

Legal entity responsible for the study

None

Funding

None

Disclosure

All authors have declared no conflicts of interest.